Inventiva SA

03/13/2024 | Press release | Distributed by Public on 03/13/2024 16:27

Inventiva annonce la présentation des résultats de son étude clinique de Phase IIa LEGEND combinant lanifibranor et empagliflozine chez des patients atteints de MASH/NASH et de DT2

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.